Variable Hematoloji / Metabolik Hastalıklar

Lysosomal Storage Diseases and Gaucher Disease

GAUCHER DISEASE is one of the MOST EASILY OVERLOOKED and MOST EFFECTIVELY TREATABLE diseases in hematology practice. Due to the deficiency of the enzyme glucocerebrosidase, accumulation occurs in macrophages, and these cells fill the spleen, liver, and bone marrow; the resulting picture is SPLENOMEGALY, THROMBOCYTOPENIA, ANEMIA, and BONE PAIN.

This quartet closely MIMICS hematologic malignancies, and patients are often evaluated with suspicion of leukemia or lymphoma. MAKING THE DIAGNOSIS IS SURPRISINGLY EASY:

GLUCOCEREBROSIDASE ENZYME ACTIVITY is measured in dry blood spots or leukocytes; GAUCHER CELLS can be seen in bone marrow aspiration, but this is NOT MANDATORY for diagnosis, and a diagnosis should not be made without the enzyme test. TREATMENT IS EFFECTIVE:

ENZYME REPLACEMENT THERAPY and substrate reduction therapy significantly reduce splenomegaly, cytopenias, and bone findings. Therefore, considering Gaucher disease in a case of "unexplained splenomegaly + thrombocytopenia" prevents unnecessary interventions and identifies a treatable disease.

CRITICAL WARNING: SPLENECTOMY should be AVOIDED nowadays as it WORSENS bone and lung involvement; additionally, Gaucher patients have an increased risk of PARKINSON'S DISEASE and MULTIPLE MYELOMA.

Rapid management

Think of GAUCHER DISEASE when you see UNEXPLAINED SPLENOMEGALY + THROMBOCYTOPENIA (± anemia, bone pain); this picture mimics hematologic malignancies and patients are often monitored with suspicion of leukemia/lymphoma.
DIAGNOSIS IS EASY:
Measurement of GLUCOSEREBROSIDASE ENZYME ACTIVITY (dry blood spot or leukocytes) confirms the diagnosis; genetic confirmation is performed.
GAUCHER CELLS may be seen in the bone marrow, but it is NOT REQUIRED FOR DIAGNOSIS and alone is not sufficient — similar appearing cells are found in other diseases (pseudo-Gaucher cells), therefore diagnosis should not be made without an ENZYME TEST.
TREATMENT IS EFFECTIVE: enzyme replacement therapy and substrate reduction therapy significantly reduce organomegaly and cytopenias; therefore making the diagnosis provides direct benefit.
AVOID SPLENECTOMY: it worsens bone and lung involvement; Gaucher should be excluded in every patient considered for splenectomy due to thrombocytopenia.
ALSO MONITOR: the risk of PARKINSON'S DISEASE and MULTIPLE MYELOMA is increased; bone crises, avascular necrosis, and pathological fractures may occur.
NEURONOPATHIC types (type 2 and 3) occur in children, and enzyme replacement does not correct central nervous system findings.

Drug	Adult	Pediatric	Route	Duration
Diagnostic approach in suspected Gaucher disease The diagnostic test for Gaucher disease is simple, inexpensive, and gives definitive results; however, diagnosis is often delayed for years. The reason for this contradiction is not the difficulty of the test, but the failure to consider the disease. In a patient presenting with splenomegaly and thrombocytopenia, hematologic malignancies are primarily considered and the diagnostic process is directed in that direction; bone marrow aspiration is performed, flow cytometry is requested, and when results are not conclusive, the patient begins to be monitored as 'idiopathic.' Yet, a single enzyme test can establish the diagnosis. Large macrophages with foamy cytoplasm (Gaucher cells) seen in the bone marrow support the diagnosis but are not mandatory; moreover, in conditions where cell destruction is increased, such as chronic myeloid leukemia and thalassemia, similar appearing cells (pseudo-Gaucher cells) can be found, so they are not sufficient on their own. Therefore, diagnosis should always be made by measuring enzyme activity. The dried blood spot method has significantly increased the accessibility of the test.	Measurement of GLUCOSEREBROSIDASE ENZYME ACTIVITY (in dry blood spot or peripheral blood leukocytes) is the diagnostic test; confirmation is done with GBA1 gene analysis. Bone marrow aspiration is NOT REQUIRED for diagnosis	The same test is used; neurological evaluation is performed in children to differentiate neuronopathic types	—	Diagnostic evaluation
Assessment of involvement and establishing the basis for follow-up The extent of involvement in Gaucher disease varies significantly from patient to patient; while some patients have only mild thrombocytopenia, others exhibit severe bone disease and marked organomegaly. Therefore, once diagnosed, the involvement should be systematically mapped; this map determines both the treatment decision and the monitoring frequency and provides a baseline for the evaluation of treatment response. Bone involvement is particularly important because it is the most disabling aspect of the disease and can be clinically silent; thus, it should be assessed through imaging even in the absence of symptoms. Accumulation in the bone marrow leads to bone crises, avascular necrosis, osteopenia, and pathological fractures. Lung involvement is less common but occurs in severe cases. Neurological examination is mandatory for distinguishing neuronopathic types, as this distinction directly changes the treatment expectation.	Upon diagnosis: complete blood count, measurement of liver and spleen volumes by imaging, BONE evaluation (magnetic resonance imaging and bone mineral density), biomarkers, lung assessment, and NEUROLOGICAL examination are performed; the findings form the basis for treatment decisions and follow-up.	In children, growth and pubertal development are also monitored; detailed neurological evaluation is performed regarding the neuronopathic type.	—	Repeated in diagnosis and follow-up.
Enzyme replacement and substrate reduction therapy The treatability of Gaucher disease is the main factor that determines the value of considering this diagnosis. With enzyme replacement therapy, splenomegaly and hepatomegaly significantly regress, thrombocytopenia and anemia improve, bone pain decreases, and quality of life improves. Response occurs at different rates depending on the organ: hematological findings and organ volumes improve within months, while improvement in bone findings takes years. Therefore, early initiation of treatment is important to prevent irreversible bone damage. Substrate reduction therapy works by reducing the production of the accumulated substance and offers the advantage of oral use; the choice is made according to the patient’s condition and preference. There is an important limitation in neuronopathic types: since these therapies do not cross the blood-brain barrier, they do not correct central nervous system manifestations, and this should be clearly discussed with the patient. Treatment decisions and monitoring should be carried out together with an experienced center.	ENZYME REPLACEMENT THERAPY (intravenous, at regular intervals) or SUBSTRATE REDUCTION THERAPY (oral) is used; the choice is made according to the severity of the disease, the pattern of involvement, age, and patient preference. AGENTS, DOSES, AND INTERVALS should be verified according to the protocol of the specialized center and national reimbursement conditions	In children, doses are determined according to weight; they are adjusted as growth and development are monitored	IV / oral	Generally lifelong.
Avoidance of splenectomy and monitoring of associated risks Splenectomy was frequently performed in the period before enzyme replacement therapy to correct cytopenias; however, over time, it has been understood that this approach is harmful. The spleen contains a significant portion of the accumulated substance and functions as a type of storage organ; when the spleen is removed, this load transfers to the bones, liver, and lungs. As a result, while cytopenias improve, bone disease and lung involvement worsen. The risks of asplenia itself should also be added (asplenia protocol). Therefore, today splenectomy is avoided, and the first approach is disease-specific therapy. This has a practical consequence: Gaucher disease must be excluded in every patient considered for splenectomy due to unexplained splenomegaly and thrombocytopenia; otherwise, a treatable disease would be worsened by an irreversible intervention. Moreover, Parkinson's disease and multiple myeloma risks have been shown to increase in Gaucher patients, and follow-up should also be maintained from this perspective.	SPLENECTOMY IS AVOIDED; the first approach to thrombocytopenia and organomegaly is disease-specific therapy. During follow-up, PARKINSON'S DISEASE symptoms, MULTIPLE MYELOMA, and other monoclonal gammopathies along with bone complications are evaluated.	In children, splenectomy is also avoided; growth and bone development are monitored.	—	Lifelong follow-up

Alternative

Other lysosomal storage diseases (Niemann-Pick, Fabry, Pompe) can also present with hematologic and systemic findings; in systemic manifestations unexplained by splenomegaly, this group should be considered.
Niemann-Pick disease type B can mimic Gaucher disease with splenomegaly and lung involvement; differentiation is done with enzyme and genetic tests.
Pain management and supportive care are required in bone crises; careful distinction is needed because a bone crisis can be confused with bone infection (osteomyelitis).
In severe bone involvement, orthopedic evaluation, avascular necrosis, and pathological fracture management are planned.
For bone health, calcium and vitamin D supplementation and additional treatments according to bone mineral density are considered.
Family screening and genetic counseling should be planned for every diagnosed patient; screening siblings allows early diagnosis.
Allogeneic transplantation was used in the period before enzyme replacement therapy and nowadays is limited to selected special cases.

Red flags

Not considering Gaucher disease in the case of UNEXPLAINED SPLENOMEGALY + THROMBOCYTOPENIA → a treatable disease is followed as 'idiopathic' for years and unnecessary interventions are performed.
Performing SPLENECTOMY for thrombocytopenia or splenomegaly → in Gaucher disease, BONE and LUNG involvement WORSENS; this diagnosis should be excluded in every patient considered for splenectomy.
Diagnosing Gaucher disease based solely on Gaucher-like cells seen in bone marrow without performing an ENZYME TEST → pseudo-Gaucher cells are also seen in conditions like chronic myeloid leukemia and thalassemia; diagnosis is made with ENZYME ACTIVITY.
The patient being subjected to repeated invasive procedures due to suspicion of leukemia/lymphoma because the enzyme test was not performed → a simple blood test ends this cycle.
In a Gaucher patient, new and severe bone pain, fever, and limited mobility → BONE CRISIS or OSTEOMYELITIS; differentiation is difficult and requires evaluation.
Persistent pain in the hip or shoulder → AVASCULAR NECROSIS; X-ray may be normal in the early stage, magnetic resonance imaging is required.
New monoclonal band or bone lesion in a Gaucher patient → risk of MULTIPLE MYELOMA is increased and should be evaluated (relevant protocol).
Tremor, bradykinesia, gait changes in a Gaucher patient or carrier → risk of PARKINSON'S DISEASE is increased; neurological evaluation is required.
In a child with Gaucher disease, eye movement disorder, seizures, developmental delay → NEURONOPATHIC TYPE; enzyme replacement does NOT correct central nervous system findings and this must be explained clearly to the family.

Disposition and follow-up

Green zone: Diagnosed, under treatment, and clinically stable patient: outpatient follow-up jointly with a specialized center, regular assessment of treatment response, monitoring of bone health, family screening, and planning genetic counseling.
Yellow zone: Newly diagnosed, patient planned for treatment initiation, worsening cytopenia or organomegaly, increased bone pain, diagnostic uncertainty: referral to a specialized center, detailed evaluation of involvement, review of treatment plan.
Red zone: Severe bone crisis, pathological fracture, splenic infarction or rupture, bleeding due to severe cytopenia, severe lung involvement: urgent evaluation and treatment, joint management with orthopedic and related specialty departments.

Key clinical points

READ FIRST — mimics hematologic malignancy, diagnosis is EASY

CLASSIC QUADRUPLE: SPLENOMEGALY + THROMBOCYTOPENIA + ANEMIA + BONE PAIN → suspected leukemia/lymphoma | DIAGNOSIS: GLUCOSEREBROSIDASE ENZYME ACTIVITY (dry blood spot or leukocytes) — simple, cheap, and definitive | Bone marrow aspiration NOT REQUIRED | TREATMENT IS EFFECTIVE → making the diagnosis directly benefits the patient

Gaucher disease is the best example of diseases in hematology practice that are 'easily recognized if thought of, missed for years if not.' In a patient presenting with splenomegaly and thrombocytopenia, the diagnostic process naturally focuses on hematologic malignancies; bone marrow examination is performed, flow cytometry is requested, and if the results are not conclusive, the patient is followed as 'idiopathic splenomegaly' or 'idiopathic thrombocytopenia.' This cycle can last for years, during which the patient undergoes repeated invasive procedures. Meanwhile, a single enzyme test can make the diagnosis; the dry blood spot method has made this test easily accessible. The value of the diagnosis comes from the effectiveness of the treatment: organomegaly regresses with enzyme replacement therapy, cytopenias improve, and bone pain decreases. Therefore, considering this diagnosis is not only an intellectual achievement but also an intervention that directly alters the patient’s life. Practical rule: when you see unexplained splenomegaly with thrombocytopenia, request the enzyme test.

READ FIRST — AVOID SPLENECTOMY

The spleen contains a significant portion of the accumulated substance → it acts as a type of STORAGE | When the spleen is removed, this load shifts to the BONE, LIVER, and LUNGS → cytopenias improve but BONE and LUNG INVOLVEMENT WORSENS | Additionally, the risks of asplenia are added | CONCLUSION: in any patient considered for SPLENECTOMY for thrombocytopenia/splenomegaly, GAUCHER MUST BE EXCLUDED

Splenectomy was widely performed in Gaucher patients in the period when enzyme replacement therapy was not available to correct cytopenias, and it was effective in the short term. However, long-term follow-ups revealed that this intervention worsened the course of the disease. When the mechanism is understood, the result is not surprising: the spleen is one of the largest reservoirs for macrophages that contain accumulated glucocerebroside and serves as a buffer. When this buffer is removed, accumulation shifts to other organs, especially the bone and lungs. As a result, while the blood count improves, the patient's bone disease accelerates; whereas bone disease is the most disabling and least reversible aspect of Gaucher disease. This is compounded by the inherent risks of asplenia (sepsis from encapsulated bacteria, thrombosis). The most important practical implication of this knowledge applies to undiagnosed patients: in every patient planned for splenectomy due to unexplained splenomegaly and thrombocytopenia, Gaucher disease should be excluded before making an irreversible decision.

READ FIRST — Gaucher cells do not make the diagnosis

Large macrophages with foamy cytoplasm in the bone marrow (GAUCHER CELLS) SUPPORT the diagnosis but are NOT MANDATORY | PSEUDO-GAUCHER CELLS are also seen in conditions with increased cell turnover (CHRONIC MYELOID LEUKEMIA, THALASSEMIA, myelodysplastic syndrome) | DIAGNOSIS IS ALWAYS MADE WITH ENZYME ACTIVITY

This warning prevents two types of errors. The first error is to make a direct diagnosis when Gaucher-like cells are seen in the bone marrow; however, this morphology is not specific. In conditions with increased cell turnover, macrophages intensely phagocytose cell debris and acquire a similar foamy appearance; chronic myeloid leukemia and thalassemia are classic examples of these pseudo-Gaucher cells. A Gaucher diagnosis made without an enzyme test leads both to incorrect treatment and to missing the true diagnosis. The second error is the opposite: excluding the diagnosis because Gaucher cells are not seen in the bone marrow. Bone marrow involvement can be patchy, and these cells may not be present in the sample taken; moreover, bone marrow aspiration is not mandatory for diagnosis. Both errors are prevented with the same solution: the diagnosis is made by measuring enzyme activity. This is a non-invasive, inexpensive, and definitive test; bone marrow examination is only required if there is suspicion of an accompanying hematological disease.

The response to treatment varies in speed depending on the organ

FAST (months): platelet count, hemoglobin, spleen and liver volumes | SLOW (years): BONE findings | NEVER RECOVERS: central nervous system findings in neuronopathic types (treatments do not cross the blood-brain barrier) | CONCLUSION: EARLY treatment is valuable as bone damage is irreversible

The fact that the response to treatment occurs at different speeds in different organs is important both for setting the patient's expectations correctly and understanding the timing of treatment. Hematological findings and organ volumes improve relatively quickly; the increase in platelet count and reduction in spleen size become noticeable within months, and this early response serves as a guide for both the patient and the physician. Bone findings, however, heal much more slowly, and some damage never recovers; joint damage resulting from avascular necrosis and previous fractures are permanent. This asymmetry explains why starting treatment early is valuable: hematological findings can always be corrected, but once bone damage is established, it cannot be reversed. In neuronopathic types, there is a clear limit; central nervous system findings do not improve because current treatments do not cross the blood-brain barrier. This fact should be discussed openly with the family at the start of treatment; otherwise, while systemic findings improve, the progression of neurological issues can cause an unexpected disappointment.

Accompanying risks and types

TYPE 1 (non-neuronopathic): most common; splenomegaly, cytopenias, bone disease | TYPE 2 and 3 (NEURONOPATHIC): in children, with neurological findings | INCREASED RISKS: PARKINSON'S DISEASE (in patients and CARRIERS), MULTIPLE MYELOMA and monoclonal gammopathies | BONE: bone crises, AVASCULAR NECROSIS, osteopenia, pathological fractures

The types of Gaucher disease are classified based on the presence of neurological involvement, and this distinction determines both the prognosis and the expected response to treatment. Type 1 is the most common form, there is no neurological involvement, and the response to treatment is good; therefore, most of the cases encountered in adult hematology practice are of this type. Types 2 and 3 are neuronopathic forms, occur in children, and current treatments have no effect on central nervous system findings. Understanding that changes in the GBA1 gene increase the risk of Parkinson's disease is one of the significant developments in this field; the risk is increased not only in patients but also in carriers, and this is an issue that needs to be addressed in genetic counseling. It has also been reported that the risk of multiple myeloma and monoclonal gammopathy increases; therefore, protein electrophoresis should be evaluated in follow-up. Bone disease, on the other hand, is the most disabling aspect of the disease and manifests in the form of bone crises, avascular necrosis, osteopenia, and pathological fractures. Clinically, it is difficult to distinguish a bone crisis from osteomyelitis and requires careful attention.

Featured external sources

GeneReviews Gaucher diseaseDiagnosis, types, treatment, and follow-up.
Brazilian Gaucher PCDT 2025Current official treatment protocol.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Gaucher disease is one of the easiest diseases to overlook in hematology practice but also one with the most effective treatment, and the combination of these two features makes it especially important. The disease arises due to a deficiency of the enzyme glucocerebrosidase; the material that cannot be broken down accumulates in macrophages, which fill the spleen, liver, and bone marrow.

The resulting clinical picture includes splenomegaly, thrombocytopenia, anemia, and bone pain. This quartet closely mimics hematologic malignancies; patients are often evaluated with suspicion of leukemia or lymphoma, undergo bone marrow examination, and if the results are inconclusive, they are followed for years as 'idiopathic.' Yet, making the diagnosis is surprisingly easy: measuring glucocerebrosidase enzyme activity in dried blood spots or peripheral blood leukocytes confirms the diagnosis and is verified by genetic analysis.

Large macrophages with foamy cytoplasm seen in the bone marrow (Gaucher cells) support the diagnosis, but are not mandatory; moreover, since pseudo-Gaucher cells with a similar appearance may be found in conditions with increased cell breakdown, such as chronic myeloid leukemia and thalassemia, they alone are not sufficient. Therefore, the diagnosis should always be confirmed with an enzyme test.

The value of the diagnosis comes from the effectiveness of the treatment. With enzyme replacement therapy and substrate reduction therapy, splenomegaly and hepatomegaly regress, cytopenias improve, and bone pain decreases.

The response develops at different rates depending on the organs: hematologic findings improve within months, while improvement in bone findings takes years, and some damage is irreversible. This asymmetry explains the value of early treatment.

A critical warning is also related to splenectomy: the spleen acts as a buffer containing a significant portion of the accumulated substance, so when removed, this load shifts to the bone and lungs, worsening the involvement of these organs. Therefore, splenectomy is avoided, and Gaucher disease should be ruled out in every patient considered for splenectomy due to thrombocytopenia and splenomegaly.

It is also known that the risk of Parkinson's disease and multiple myeloma is increased in these patients.

Differential diagnosis and assessment

Key considerations

Coexistence of splenomegaly and cytopenia: hematologic malignancies (leukemia, lymphoma, myeloproliferative neoplasms), Gaucher disease and other storage diseases, hypersplenism due to portal hypertension, chronic infections (visceral leishmaniasis, tuberculosis, brucellosis), autoimmune diseases, and amyloidosis should be differentiated (relevant protocols).
Foamy macrophages in the bone marrow: Gaucher disease, pseudo-Gaucher cells (chronic myeloid leukemia, thalassemia, myelodysplastic syndrome), Niemann-Pick disease, and other storage diseases should be considered; differentiation is made by enzyme testing.
Other lysosomal storage diseases: Niemann-Pick type B (splenomegaly and lung involvement), Fabry disease, and Pompe disease can present with systemic findings and should be differentiated.
New bone pain in Gaucher disease: bone crisis, osteomyelitis, avascular necrosis, pathological fracture, and accompanying malignancy should be differentiated; distinguishing bone crisis from infection is clinically difficult.
New monoclonal band in Gaucher disease: monoclonal gammopathy, multiple myeloma, and amyloidosis should be evaluated; the risk is increased in these patients (relevant protocols).
Organomegaly with neurological findings in a child: neuronopathic Gaucher types, Niemann-Pick type C, and other metabolic diseases should be considered.
The cause of thrombocytopenia: hypersplenism, bone marrow infiltration, immune thrombocytopenia, and accompanying causes should be evaluated separately.

Clinical decision reasoning

Why it matters

The reason for the existence of this protocol can be summarized in a single observation: Gaucher disease is easy to recognize but difficult to consider.

The diagnostic test is simple, inexpensive, and definitive; however, the diagnosis is often delayed for years. This contradiction exemplifies a general pattern in medicine: the obstacle to reaching a diagnosis is often conceptual rather than technical.

In a patient presenting with splenomegaly and thrombocytopenia, the mind naturally turns to hematologic malignancies; this is a correct and necessary orientation. The problem is that, after this orientation proves unfruitful, an alternative framework does not come into play.

When a patient is started on observation under the label "idiopathic," the search for a diagnosis is actually concluded. Therefore, the practical recommendation is simple and easily applicable: when you see unexplained splenomegaly with thrombocytopenia, request the enzyme test.

The main factor determining the value of the diagnosis is the effectiveness of the treatment. In diseases where nothing can be done even if diagnosed, the value of early diagnosis is limited; in Gaucher disease, the situation is quite the opposite.

With enzyme replacement therapy, organomegaly regresses, cytopenias improve, and the patient's quality of life significantly increases. Therefore, considering this diagnosis is a direct clinical gain rather than an intellectual satisfaction.

The fact that the response to treatment develops at different speeds in different organs explains the importance of timing. Hematological findings can always be corrected; whereas bone damage, especially joint destruction resulting from avascular necrosis, is irreversible.

This asymmetry shows why early initiation of treatment not only leads to 'better' outcomes but also creates a lasting difference, and explains why bone assessment should be performed without waiting for symptoms. The issue of splenectomy is an instructive example of how medical thinking has changed over time.

In the period before enzyme replacement therapy, splenectomy seemed a logical intervention because it corrected cytopenias, and it was widely applied. Long-term follow-ups, however, showed an unexpected result: while blood counts improved, bone disease accelerated.

When the mechanism was understood, this result became explainable; the spleen served as a buffer for the accumulated substance, and when this buffer was removed, the load shifted to the bones and lungs. The lesson here is that the correction of a measured parameter by an intervention does not necessarily mean improvement of the disease course.

The most critical practical consequence of this information is for patients who have not yet been diagnosed: splenectomy is an irreversible decision, and excluding Gaucher disease beforehand prevents the permanent worsening of a treatable disease. Finally, the warning that the Gaucher cell does not dictate the diagnosis illustrates the limits of morphology-based diagnosis.

Macrophages acquire a similar foamy appearance in conditions of intense cell destruction; therefore, morphology is supportive but not decisive. Similarly, because bone marrow involvement may be patchy, the absence of these cells does not exclude the diagnosis.

Both errors are prevented by the same solution: the diagnosis is made through enzyme activity.

Safety and monitoring

Complications and safety

Critical complications

Bone disease is the most disabling aspect of Gaucher disease; bone crises, avascular necrosis, osteopenia, and pathological fractures are seen, and some of this damage is irreversible.
Worsening of bone and lung involvement after splenectomy leads to irreversible deterioration.
Bleeding due to severe thrombocytopenia and fatigue due to anemia disrupt quality of life.
Splenic infarction due to massive splenomegaly and, rarely, rupture may develop.
Lung involvement can lead to interstitial lung disease and pulmonary hypertension.
The risk of multiple myeloma and monoclonal gammopathy is increased; other malignancy risks have also been reported.
The risk of Parkinson's disease has increased in both patients and carriers.
In neuropathic types, neurological findings do not improve with current treatments and may progress.

Special patient populations

Special considerations

Children: neuropathic types (types 2 and 3) are seen in this age group; growth retardation and delayed puberty should also be evaluated.
Patients with neuropathic types: current treatments do not correct central nervous system findings; this should be clearly discussed with the family and supportive care should be planned.
Patients who have undergone splenectomy: bone and lung involvement is more severe; protection against encapsulated bacteria and vaccination is also required (asplenia protocol).
Pregnant women: cytopenias and bone findings may worsen during pregnancy; treatment decisions should be made together with a specialized center and obstetrics (relevant protocol).
Family members and carriers: screening siblings allows early diagnosis; the increased risk of Parkinson's disease in carriers should be addressed in genetic counseling.
Patients from specific ethnic backgrounds: the frequency of the disease is significantly higher in some communities, and this information should increase diagnostic suspicion.
Elderly patients: should be evaluated for signs of Parkinson's disease, and screened for monoclonal gammopathy and myeloma.
Patients with orthopedic complications: management of avascular necrosis and pathological fractures should be planned jointly with orthopedics.

Follow-up and reassessment

Follow-up plan

Follow-up in Gaucher disease should be conducted together with an experienced center and in a systematic manner. When the diagnosis is made, a detailed map of involvement should be created; blood count, liver and spleen volumes, bone assessment, lung findings, and neurological examination should be recorded.

These baseline values are necessary to measure the response to treatment. In patients under treatment, hematologic findings and organ volumes should be monitored at regular intervals; if the expected response is not obtained, adherence, dose, and diagnosis should be re-evaluated.

Bone assessment should be performed at appropriate intervals without waiting for symptoms because bone involvement can progress silently, and damage is irreversible; bone mineral density and imaging should be repeated according to the institutional protocol. In newly emerging bone pain, bone crisis, avascular necrosis, pathological fracture, and osteomyelitis should be distinguished; because distinguishing bone crisis from infection is clinically difficult, careful assessment is required.

Associated risks should also be considered during follow-up. Monoclonal gammopathy screening should be performed with serum protein electrophoresis, and detected bands should be evaluated for myeloma.

Neurological examination should be performed at every visit; tremor, bradykinesia, and gait changes should be questioned regarding Parkinson's disease. In patients with lung findings, pulmonary function tests and imaging should be planned if necessary.

In patients who have undergone splenectomy, vaccination against encapsulated bacteria and an emergency plan should be provided. Family screening and genetic counseling should be planned for every diagnosed patient; screening of siblings allows early detection of cases that have not yet shown symptoms, creating an opportunity to start treatment before bone damage develops.

Carrier status and risk of Parkinson's disease should be handled sensitively during genetic counseling. Patients should be provided with written information about their disease, the treatments they use, and the need to avoid splenectomy; they should be asked to share this information with every physician they consult.

In patients with the neuronopathic type, follow-up should be conducted in a multidisciplinary manner, and neurological progression and supportive care needs should be regularly evaluated. Since access to treatment and reimbursement conditions can affect the continuity of follow-up in our country, this process should also be monitored, and treatment interruptions should be avoided.